Last reviewed · How we verify
Vaso-occlusive crisis in sickle cell disease — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Selg1 | CRIZANLIZUMAB | Novartis | Selectin Blocker [EPC] | P-selectin | 2019-01-01 | |
| ADAKVEO | CRIZANLIZUMAB-TMCA | NOVARTIS PHARMS CORP | Selectin Blocker [EPC] | P-selectin |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- NOVARTIS PHARMS CORP · 1 drug in Vaso-occlusive crisis in sickle cell disease
- Novartis · 1 drug in Vaso-occlusive crisis in sickle cell disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Vaso-occlusive crisis in sickle cell disease:
- Vaso-occlusive crisis in sickle cell disease treatment updates — RSS
- Vaso-occlusive crisis in sickle cell disease treatment updates — Atom
- Vaso-occlusive crisis in sickle cell disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Vaso-occlusive crisis in sickle cell disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/vaso-occlusive-crisis-in-sickle-cell-disease. Accessed 2026-06-10.
Related
- Vaso-occlusive crisis in sickle cell disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing